Immunovia
In Brief This Week: Natera, Caris Life Sciences, Fulgent Genetics, Castle Biosciences, More
News items for the week of April 25, 2022
Immunovia, JW BioScience Ink Licensing Agreement for Early Pancreatic Cancer Detection Biomarkers
Immunovia said that it has secured intellectual property rights to the biomarkers, which are part of the diagnostic signature for its Immray PanCan-d blood test.
The company also published a study describing ImmRay PanCan-D biomarker signature that it said could be used to detect early-stage pancreatic cancer.
Immunovia Raises $37.1M
The Swedish molecular diagnostics firm will use the proceeds, in part, to fund the planned launch of its Immray PanCan-d assay for detecting pancreatic cancer.